The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut. 2010 May; 59(5):630-7.

View in: PubMed

subject areas

Amylases
Angiotensin-Converting Enzyme Inhibitors
Animals
Anticarcinogenic Agents
Aspirin
Carcinoma in Situ
Carcinoma, Pancreatic Ductal
Disease Models, Animal
Disease Progression
Drug Evaluation, Preclinical
Enalapril
Gene Expression Regulation, Neoplastic
Mice
Mice, Transgenic
Neoplasm Invasiveness
NF-kappa B
Pancreatic Neoplasms
Receptor, Angiotensin, Type 1

authors with profiles

ANIRBAN MAITRA